Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 11/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.38 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.38 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.38 |
| ▸ | GNPAT | O15228 | 1/20 | 0.37 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.35 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21440847 | 0.94 | NOD1 (0.36) | NOD1FOLH1RIMKLANAALAD2GLO1 | |
| SCHEMBL25662195 | 0.94 | NOD1 (0.36) | NOD1FOLH1RIMKLANAALAD2GLO1 | |
| SCHEMBL25662197 | 0.94 | NOD1 (0.36) | NOD1FOLH1RIMKLANAALAD2GLO1 | |
| SCHEMBL17040489 | 0.86 | NOD1 (0.49) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL25662203 | 0.86 | NOD1 (0.54) | NOD1FOLH1GLO1PTGS1GSTK1 | |
| SCHEMBL23872080 | 0.86 | NOD1 (0.47) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL21242721 | 0.84 | NOD1 (0.53) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL21242989 | 0.84 | NOD1 (0.53) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL21440833 | 0.84 | NOD1 (0.53) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL12118226 | 0.84 | NOD1 (0.53) | NOD1FOLH1RIMKLANAALAD2GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | disclosed |
| WO-2021193983-A2 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, GRPR | NOD1 2186/4885FOLH1 736/4885RIMKLA 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.